Hims is officially phasing out its copycat weight-loss drugs
Shares of Hims & Hers Health plunged Friday after the Food & Drug Administration said a shortage of the active ingredient in ...
Hims & Hers Health shares tumbled despite the telehealth provider beating fourth-quarter expectations and offering ...
Hims & Hers Health reported fourth-quarter results on Monday that beat analysts’ expectations, but the stock sank in extended ...
The ruling shows Novo Nordisk’s confidence that the supply of semaglutide will be stable for now.
Shares of Hims & Hers Health ( HIMS -25.79%) are falling on Friday. The company's stock lost 23.2% as of 1 p.m. ET and lost ...
Hims & Hers Health (HIMS) has seen its shares decline over 17% in the past week since the U.S. Food and Drug Administration (FDA) announced ...
Super Micro has until Tuesday to file delayed financial accounts or risk being delisted by the Nasdaq stock exchange, ...
Online health and wellness company Hims & Hers reported fourth-quarter earnings that beat Wall Street analysts' expectations ...
Shares of direct-to-consumer telehealth platform Hims & Hers Health (NYSE: HIMS) have become a runaway freight train. The ...
Semaglutide is a glucagon-like peptide-1 (GLP-1) that helps regulate blood sugar levels. Because of outsized demand for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback